{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:33:59Z","timestamp":1788878039708,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tuberculous meningitis (TBM)\u2013related deaths occur early, often within weeks after treatment initiation. Enhanced treatment early in the disease course with agents that effectively penetrate the central nervous system may improve outcomes in TBM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a phase 2, open-label, randomized trial in Masaka, Uganda, to assess the safety and tolerability of linezolid 1200 mg once daily versus no linezolid with high-dose (35\u2005mg\/kg\/d) or standard-dose (10\u2005mg\/kg\/d) rifampin for 4 weeks in participants with definite or suspected TBM. The primary endpoint was any grade \u22653 adverse event during the interventional period. Secondary endpoints included overall survival and functional independence adjusted for TBM disease grade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We randomized 40 participants (98% with human immunodeficiency virus [HIV]). One-fourth had microbiologically confirmed TBM. Nearly 75% had moderate to severe disease (Medical Research Council grades II and III). No significant difference in grade \u22653 adverse event\u2013\u00adfree survival was observed across the 4 treatment arms (P = .18) or by linezolid (P = .97) or rifampin (P = .46) treatment group. More favorable overall survival at 12 and 24 weeks (odds ratio, 0.28 [P = .10] and 0.43 [P = .24], respectively) and functional outcome at 12 and 24 weeks (OR for lower modified Rankin Scale score [ie, less disability], 2.22 [P = .18] and 2.00 [P = .24]) were observed in the linezolid group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The addition of a short course of linezolid to treat predominantly moderate to severe TBM in adults with HIV did not introduce excess toxicity. Our findings add to growing evidence that linezolid is a safe and acceptable treatment for TBM that merits further investigation in larger multisite trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf089","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:55:16Z","timestamp":1739796916000},"page":"e1034-e1044","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9440-9349","authenticated-orcid":false,"given":"Felicia C","family":"Chow","sequence":"first","affiliation":[{"name":"Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Medicine (Infectious Diseases), University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"UCSF Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paddy","family":"Kafeero","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nakimbugwe","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ssemaganda","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colman","family":"Tayebwa","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3390-1749","authenticated-orcid":false,"given":"Elana","family":"Farrell","sequence":"additional","affiliation":[{"name":"Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3476-1100","authenticated-orcid":false,"given":"Margaret","family":"Wilson","sequence":"additional","affiliation":[{"name":"Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":false,"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[{"name":"UCSF Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[{"name":"UCSF Center for Tuberculosis, University of California, San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-532X","authenticated-orcid":false,"given":"Fiona","family":"Cresswell","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]},{"name":"Clinical Research Department, London School of Hygiene and Tropical Medicine , London ,","place":["United Kingdom"]},{"name":"Clinical Research, Infectious Diseases Institute , Kampala ,","place":["Uganda"]},{"name":"Global Health and Infection, Brighton and Sussex Medical School , Brighton ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-1571","authenticated-orcid":false,"given":"Freddie M","family":"Kibengo","sequence":"additional","affiliation":[{"name":"Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit , Entebbe ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025071111114288100_jiaf089-B1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nature Reviews Neurology"},{"key":"2025071111114288100_jiaf089-B2","doi-asserted-by":"crossref","first-page":"e27821","DOI":"10.1371\/journal.pone.0027821","article-title":"Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents.","volume":"6","author":"T\u00f6r\u00f6k","year":"2011","journal-title":"PLoS One"},{"key":"2025071111114288100_jiaf089-B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/cid\/cix230","article-title":"Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen","volume":"65","author":"Heemskerk","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1468-1331.2006.01534.x","article-title":"Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis","volume":"14","author":"Kalita","year":"2007","journal-title":"Eur J Neurol"},{"key":"2025071111114288100_jiaf089-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2025071111114288100_jiaf089-B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s15010-003-3179-1","article-title":"Tuberculous meningitis in adults: review of 61 cases","volume":"31","author":"S\u00fctla\u015f","year":"2003","journal-title":"Infection"},{"key":"2025071111114288100_jiaf089-B7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12879-018-3633-4","article-title":"Mortality in hospitalized patients with tuberculous meningitis","volume":"19","author":"Soria","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025071111114288100_jiaf089-B8","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/cid\/ciy445","article-title":"Predicting mortality of tuberculous meningitis","volume":"67","author":"Dian","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2013associated tuberculous meningitis","volume":"52","author":"T\u00f6r\u00f6k","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe1511990","article-title":"Chemotherapy for tuberculous meningitis","volume":"374","author":"Donald","year":"2016","journal-title":"New Engl J Med"},{"key":"2025071111114288100_jiaf089-B11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/cid\/ciab162","article-title":"High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a phase II open-label randomized controlled trial","volume":"73","author":"Cresswell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12688\/wellcomeopenres.15565.2","article-title":"High dose oral rifampicin to improve survival from adult tuberculous meningitis: a randomised placebo-controlled double-blinded phase III trial (the HARVEST study)","volume":"4","author":"Marais","year":"2020","journal-title":"Wellcome Open Res"},{"key":"2025071111114288100_jiaf089-B13","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1128\/AAC.02784-14","article-title":"Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis","volume":"58","author":"Sun","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071111114288100_jiaf089-B14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2025071111114288100_jiaf089-B15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2025071111114288100_jiaf089-B16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/01.wnl.0000187119.33075.41","article-title":"Evaluation of a clinical screening tool for HIV-associated sensory neuropathies","volume":"65","author":"Cherry","year":"2005","journal-title":"Neurology"},{"key":"2025071111114288100_jiaf089-B17","author":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services"},{"key":"2025071111114288100_jiaf089-B18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","article-title":"Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials","volume":"38","author":"Banks","year":"2007","journal-title":"Stroke"},{"key":"2025071111114288100_jiaf089-B19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","article-title":"Improving the assessment of outcomes in stroke","volume":"33","author":"Wilson","year":"2002","journal-title":"Stroke"},{"key":"2025071111114288100_jiaf089-B20","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/STROKEAHA.109.571364","article-title":"Improving the reliability of stroke disability grading in clinical trials and clinical practice","volume":"41","author":"Saver","year":"2010","journal-title":"Stroke"},{"key":"2025071111114288100_jiaf089-B21","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus\u2013associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B22","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.tube.2023.102351","article-title":"Escalate: linezolid as an add on treatment in the intensive phase of tubercular meningitis: a randomized controlled pilot trial","volume":"142","author":"Sahib","year":"2023","journal-title":"Tuberculosis"},{"key":"2025071111114288100_jiaf089-B23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12916-018-1033-7","article-title":"Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"16","author":"Tweed","year":"2018","journal-title":"BMC Med"},{"key":"2025071111114288100_jiaf089-B24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2025071111114288100_jiaf089-B25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"2025071111114288100_jiaf089-B27","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025071111114288100_jiaf089-B28","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025071111114288100_jiaf089-B29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025071111114288100_jiaf089-B30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2025071111114288100_jiaf089-B31","doi-asserted-by":"crossref","first-page":"ofaa257","DOI":"10.1093\/ofid\/ofaa257","article-title":"Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis","volume":"7","author":"Stadelman","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025071111114288100_jiaf089-B32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.19-0098","article-title":"Early mortality among immunocompetent patients of tuberculous meningitis: a prospective study","volume":"101","author":"Jaipuriar","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2025071111114288100_jiaf089-B33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2217\/fmb.12.86","article-title":"Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome","volume":"7","author":"Brancusi","year":"2012","journal-title":"Future Microbiol"},{"key":"2025071111114288100_jiaf089-B34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3201\/eid2803.212230","article-title":"Treatment outcomes of childhood tuberculous meningitis in a real-world retrospective cohort, Bandung, Indonesia","volume":"28","author":"Nataprawira","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025071111114288100_jiaf089-B35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2025071111114288100_jiaf089-B36","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"New Engl J Med"},{"key":"2025071111114288100_jiaf089-B37","first-page":"261","article-title":"Outcome of tuberculous meningitis at 6 and 12 months: a multiple regression analysis","volume":"3","author":"Kalita","year":"1999","journal-title":"Int J Tuberc Lung"},{"key":"2025071111114288100_jiaf089-B38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"New Engl J Medicine"},{"key":"2025071111114288100_jiaf089-B39","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jac\/dku103","article-title":"Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial","volume":"69","author":"Kalita","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025071111114288100_jiaf089-B40","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41467-022-29353-x","article-title":"Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics","volume":"13","author":"Ramachandran","year":"2022","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf089\/61932687\/jiaf089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/e1034\/61932687\/jiaf089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/e1034\/61932687\/jiaf089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T15:11:51Z","timestamp":1752246711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/6\/e1034\/8019639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf089","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,2,17]]}}}